Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 128

1.

Cardiovascular events in cancer survivors.

Howard E, Steingart RM, Armstrong GT, Lyon AR, Armenian SH, Teresa Voso M, Cicconi L, Coco FL, Minotti G.

Semin Oncol. 2019 Dec;46(6):426-432. doi: 10.1053/j.seminoncol.2019.01.007. Epub 2019 Nov 19. Review.

PMID:
31791551
2.

Cardio-oncological management of patients.

Cardinale DM, Barac A, Torbicki A, Khandheria BK, Lenihan D, Minotti G.

Semin Oncol. 2019 Dec;46(6):408-413. doi: 10.1053/j.seminoncol.2019.11.002. Epub 2019 Nov 19. Review.

PMID:
31784042
3.

Helping the cardio-oncologist: from real life to guidelines.

Armenian SH, Jurczak W, Carver JR, Gennari A, Minotti G, Ewer MS.

Semin Oncol. 2019 Dec;46(6):433-436. doi: 10.1053/j.seminoncol.2019.01.005. Epub 2019 Nov 20. Review.

PMID:
31784041
4.

Treatment specific toxicities: Hormones, antihormones, radiation therapy.

Plummer C, Steingart RM, Jurczak W, Iakobishvili Z, Lyon AR, Plastaras JP, Minotti G.

Semin Oncol. 2019 Dec;46(6):414-420. doi: 10.1053/j.seminoncol.2019.01.006. Epub 2019 Nov 19. Review.

PMID:
31784040
5.

Old and new directions of Cardio-Oncology.

Ewer MS, Carver JR, Minotti G.

Semin Oncol. 2019 Dec;46(6):395-396. doi: 10.1053/j.seminoncol.2019.11.003. Epub 2019 Nov 18. No abstract available.

PMID:
31767271
6.

Cardio-oncology in clinical studies and real life.

Dent SF, Suter TM, López-Fernández T, Opolski G, Menna P, Minotti G.

Semin Oncol. 2019 Dec;46(6):421-425. doi: 10.1053/j.seminoncol.2019.01.004. Epub 2019 Nov 18.

PMID:
31767270
7.

Mechanisms and clinical course of cardiovascular toxicity of cancer treatment I. Oncology.

Yeh ETH, Ewer MS, Moslehi J, Dlugosz-Danecka M, Banchs J, Chang HM, Minotti G.

Semin Oncol. 2019 Dec;46(6):397-402. doi: 10.1053/j.seminoncol.2019.10.006. Epub 2019 Nov 11. Review.

PMID:
31753424
8.

Mechanisms and clinical course of cardiovascular toxicity of cancer treatment II. Hematology.

Breccia M, Carver JR, Szmit S, Jurczak W, Salvatorelli E, Minotti G.

Semin Oncol. 2019 Dec;46(6):403-407. doi: 10.1053/j.seminoncol.2019.10.005. Epub 2019 Nov 11.

PMID:
31748121
9.

Efficacy and safety of low dose ponatinib in a case of Ph-positive acute lymphoblastic leukaemia.

Marchesi F, Salvatorelli E, Renzi D, Mengarelli A, Minotti G, Menna P.

Br J Haematol. 2019 Oct;187(1):e15-e17. doi: 10.1111/bjh.16132. Epub 2019 Aug 1. No abstract available.

PMID:
31368155
10.

Pharmacology of Ranolazine versus Common Cardiovascular Drugs in Patients with Early Diastolic Dysfunction Induced by Anthracyclines or Nonanthracycline Chemotherapeutics: A Phase 2b Minitrial.

Minotti G, Menna P, Calabrese V, Greco C, Armento G, Annibali O, Marchesi F, Salvatorelli E, Reggiardo G.

J Pharmacol Exp Ther. 2019 Aug;370(2):197-205. doi: 10.1124/jpet.119.258178. Epub 2019 May 17.

PMID:
31101682
11.

Correction to: Cardiotoxicity of Targeted Cancer Drugs: Concerns, "The Cart Before the Horse," and Lessons from Trastuzumab.

Menna P, Minotti G, Salvatorelli E.

Curr Cardiol Rep. 2019 Apr 15;21(5):40. doi: 10.1007/s11886-019-1131-y.

PMID:
30989376
12.

Cardiotoxicity of Targeted Cancer Drugs: Concerns, "The Cart Before the Horse," and Lessons from Trastuzumab.

Menna P, Minotti G, Salvatorelli E.

Curr Cardiol Rep. 2019 Mar 18;21(5):33. doi: 10.1007/s11886-019-1121-0. Review. Erratum in: Curr Cardiol Rep. 2019 Apr 15;21(5):40.

PMID:
30887161
13.

Isavuconazole: Case Report and Pharmacokinetic Considerations.

Marchesi F, Girmenia C, Goffredo BM, Salvatorelli E, Romano A, Mengarelli A, Minotti G, Menna P.

Chemotherapy. 2018;63(5):253-256. doi: 10.1159/000494329. Epub 2018 Nov 20.

PMID:
30458443
14.

The Endogenous Lusitropic and Chronotropic Agent, B-Type Natriuretic Peptide, Limits Cardiac Troponin Release in Cancer Patients with an Early Impairment of Myocardial Relaxation Induced by Anthracyclines.

Menna P, Salvatorelli E, Armento G, Annibali O, Greco C, Marchesi F, Calabrese V, Reggiardo G, Minotti G.

J Pharmacol Exp Ther. 2018 Dec;367(3):518-527. doi: 10.1124/jpet.118.253104. Epub 2018 Oct 1.

PMID:
30275150
15.

Pixantrone: novel mode of action and clinical readouts.

Minotti G, Han H, Cattan V, Egorov A, Bertoni F.

Expert Rev Hematol. 2018 Jul;11(7):587-596. doi: 10.1080/17474086.2018.1476848. Epub 2018 Jun 18. Review.

PMID:
29912583
16.

Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: the possible role of ponatinib.

Breccia M, Efficace F, Iurlo A, Luciano L, Abruzzese E, Gozzini A, Pregno P, Tiribelli M, Rosti G, Minotti G.

Expert Opin Drug Saf. 2018 Jun;17(6):623-628. doi: 10.1080/14740338.2018.1480719. Epub 2018 May 30. Review.

PMID:
29845876
17.

The International Cardioncology Society-ONE trial: Not all that glitters is for cardioncologists only.

Minotti G.

Eur J Cancer. 2018 Jul;97:27-29. doi: 10.1016/j.ejca.2018.04.003. Epub 2018 May 3. No abstract available.

PMID:
29731230
18.

Pharmacology of Cardio-Oncology: Chronotropic and Lusitropic Effects of B-Type Natriuretic Peptide in Cancer Patients with Early Diastolic Dysfunction Induced by Anthracycline or Nonanthracycline Chemotherapy.

Menna P, Calabrese V, Armento G, Annibali O, Greco C, Salvatorelli E, Marchesi F, Reggiardo G, Minotti G.

J Pharmacol Exp Ther. 2018 Jul;366(1):158-168. doi: 10.1124/jpet.118.249235. Epub 2018 May 2.

PMID:
29720563
19.

Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding.

Boriani G, Corradini P, Cuneo A, Falanga A, Foà R, Gaidano G, Ghia PP, Martelli M, Marasca R, Massaia M, Mauro FR, Minotti G, Molica S, Montillo M, Pinto A, Tedeschi A, Vitolo U, Zinzani PL.

Hematol Oncol. 2018 Oct;36(4):624-632. doi: 10.1002/hon.2503. Epub 2018 Mar 7. Review.

PMID:
29512173
20.

Editorial: The Journal Chemotherapy Is for Cardio-Oncologists Too.

Minotti G.

Chemotherapy. 2018 Feb 9;63(2):53-54. doi: 10.1159/000487055. [Epub ahead of print] No abstract available.

PMID:
29428941
21.

Early Diastolic Dysfunction after Cancer Chemotherapy: Primary Endpoint Results of a Multicenter Cardio-Oncology Study.

Calabrese V, Menna P, Annibali O, Armento G, Carpino A, Cerchiara E, Greco C, Marchesi F, Spallarossa P, Toglia G, Reggiardo G, Minotti G; Collaborators.

Chemotherapy. 2018;63(2):55-63. doi: 10.1159/000486761. Epub 2018 Feb 9. Erratum in: Chemotherapy. 2018 Apr 10;63(2):64.

PMID:
29428939
22.

Modified Colistin Regimen for Critically Ill Patients with Acute Renal Impairment and Continuous Renal Replacement Therapy.

Menna P, Salvatorelli E, Mattei A, Cappiello D, Minotti G, Carassiti M.

Chemotherapy. 2018;63(1):35-38. doi: 10.1159/000484974. Epub 2017 Dec 22.

23.

Low-Dose Anthracycline and Risk of Heart Failure in a Pharmacokinetic Model of Human Myocardium Exposure: Analog Specificity and Role of Secondary Alcohol Metabolites.

Salvatorelli E, Menna P, Chello M, Covino E, Minotti G.

J Pharmacol Exp Ther. 2018 Feb;364(2):323-331. doi: 10.1124/jpet.117.246140. Epub 2017 Dec 8.

PMID:
29222131
24.

Early diagnosis of acute coronary syndrome.

Katus H, Ziegler A, Ekinci O, Giannitsis E, Stough WG, Achenbach S, Blankenberg S, Brueckmann M, Collinson P, Comaniciu D, Crea F, Dinh W, Ducrocq G, Flachskampf FA, Fox KAA, Friedrich MG, Hebert KA, Himmelmann A, Hlatky M, Lautsch D, Lindahl B, Lindholm D, Mills NL, Minotti G, Möckel M, Omland T, Semjonow V.

Eur Heart J. 2017 Nov 1;38(41):3049-3055. doi: 10.1093/eurheartj/ehx492.

PMID:
29029109
25.

Cancer drugs and QT prolongation: weighing risk against benefit.

Menna P, Salvatorelli E, Minotti G.

Expert Opin Drug Saf. 2017 Oct;16(10):1099-1102. doi: 10.1080/14740338.2017.1354987. Epub 2017 Jul 20. No abstract available.

PMID:
28699784
26.

Modeling Human Myocardium Exposure to Doxorubicin Defines the Risk of Heart Failure from Low-Dose Doxorubicin.

Salvatorelli E, Menna P, Chello M, Covino E, Minotti G.

J Pharmacol Exp Ther. 2017 Aug;362(2):263-270. doi: 10.1124/jpet.117.242388. Epub 2017 May 30.

PMID:
28559479
27.

Do You Know Pixantrone?

Minotti G, Menna P, Salvatorelli E.

Chemotherapy. 2017;62(3):192-193. doi: 10.1159/000464276. Epub 2017 Mar 24. No abstract available.

28.

The Influence of Dietary Components on Early Signs of Atherosclerosis in Apparently Healthy Young-adult Males: An Observational Study of 615 Subjects.

Minotti GC, Cortese F, Corsonello A, Guadalupi G, D Arcangelo AP, Palumbo SD, Naio R, Clemente O, Aurelio A, Carone S, Gelsumino T, Gemignani V, Bianchini E, Vigotti M, Faita F, Greco L, Primerano R, Incalzi RA, Ciccone MM.

Curr Vasc Pharmacol. 2017;15(5):482-490. doi: 10.2174/1570161115666170201111809.

PMID:
28155612
29.

Valsalva maneuver in phlebologic practice.

Ricci S, Moro L, Minotti GC, Incalzi RA, De Maeseneer M.

Phlebology. 2018 Mar;33(2):75-83. doi: 10.1177/0268355516678513. Epub 2017 Jan 12.

PMID:
28081660
30.

Identification, prevention and management of cardiovascular risk in chronic myeloid leukaemia patients candidate to ponatinib: an expert opinion.

Breccia M, Pregno P, Spallarossa P, Arboscello E, Ciceri F, Giorgi M, Grossi A, Mallardo M, Nodari S, Ottolini S, Sala C, Tortorella G, Rosti G, Pane F, Minotti G, Baccarani M.

Ann Hematol. 2017 Apr;96(4):549-558. doi: 10.1007/s00277-016-2820-x. Epub 2016 Sep 30. Review.

PMID:
27686083
31.

Heart Rate reduction by IVabradine for improvement of ENDothELial function in patients with coronary artery disease: the RIVENDEL study.

Mangiacapra F, Colaiori I, Ricottini E, Balducci F, Creta A, Demartini C, Minotti G, Di Sciascio G.

Clin Res Cardiol. 2017 Jan;106(1):69-75. doi: 10.1007/s00392-016-1024-7. Epub 2016 Aug 12.

PMID:
27520989
32.

Rethinking Drugs from Chemistry to Therapeutic Opportunities: Pixantrone beyond Anthracyclines.

Menna P, Salvatorelli E, Minotti G.

Chem Res Toxicol. 2016 Aug 15;29(8):1270-8. doi: 10.1021/acs.chemrestox.6b00190. Epub 2016 Jul 22.

PMID:
27420111
33.

Drug-induced hepatotoxicity in cancer patients - implication for treatment.

Vincenzi B, Armento G, Spalato Ceruso M, Catania G, Leakos M, Santini D, Minotti G, Tonini G.

Expert Opin Drug Saf. 2016 Sep;15(9):1219-38. doi: 10.1080/14740338.2016.1194824. Epub 2016 Jun 14. Review.

PMID:
27232067
34.

Critical concepts, practice recommendations, and research perspectives of pixantrone therapy in non-Hodgkin lymphoma: a SIE, SIES, and GITMO consensus paper.

Zinzani PL, Corradini P, Martelli M, Minotti G, Oliva S, Spina M, Barosi G, Tura S.

Eur J Haematol. 2016 Dec;97(6):554-561. doi: 10.1111/ejh.12768. Epub 2016 Jul 1.

PMID:
27124765
35.

Editorial.

Minotti G, Graziani G, Delogu G.

Chemotherapy. 2016;61(1):1-2. doi: 10.1159/000441664. Epub 2015 Nov 3. No abstract available.

36.

Managing anthracycline-induced cardiotoxicity: beginning with the end in mind.

Salvatorelli E, Menna P, Minotti G.

Future Cardiol. 2015 Jul;11(4):363-6. doi: 10.2217/FCA.15.35. Epub 2015 Aug 4. No abstract available.

37.

The concomitant management of cancer therapy and cardiac therapy.

Salvatorelli E, Menna P, Cantalupo E, Chello M, Covino E, Wolf FI, Minotti G.

Biochim Biophys Acta. 2015 Oct;1848(10 Pt B):2727-37. doi: 10.1016/j.bbamem.2015.01.003. Epub 2015 Jan 14. Review.

38.

Telaprevir raises the plasma/whole blood ribavirin ratio: trying to come full circle on a dangerous relationship.

Menna P, Gallo P, Vespasiani Gentilucci U, Salvatorelli E, Galati G, Minotti G, Picardi A.

J Viral Hepat. 2014 Oct;21(10):e136-7. doi: 10.1111/jvh.12264. Epub 2014 Jun 16. No abstract available.

PMID:
24935352
39.

Report on the international colloquium on cardio-oncology (rome, 12-14 march 2014).

Ewer M, Gianni L, Pane F, Sandri MT, Steiner RK, Wojnowski L, Yeh ET, Carver JR, Lipshultz SE, Minotti G, Armstrong GT, Cardinale D, Colan SD, Darby SC, Force TL, Kremer LC, Lenihan DJ, Sallan SE, Sawyer DB, Suter TM, Swain SM, van Leeuwen FE.

Ecancermedicalscience. 2014 May 29;8:433. doi: 10.3332/ecancer.2014.433. eCollection 2014.

40.

Low level tumor necrosis factor-alpha protects cardiomyocytes against high level tumor necrosis factor-alpha: brief insight into a beneficial paradox.

Cacciapaglia F, Salvatorelli E, Minotti G, Afeltra A, Menna P.

Cardiovasc Toxicol. 2014 Dec;14(4):387-92. doi: 10.1007/s12012-014-9257-z.

PMID:
24798036
41.

Development of a tumor-specific photoactivatable doxorubicin prodrug.

Girotti AW, Minotti G.

Photochem Photobiol. 2013 Sep-Oct;89(5):1009-10. doi: 10.1111/php.12151. Epub 2013 Sep 3.

42.

Pharmacology at work for cardio-oncology: ranolazine to treat early cardiotoxicity induced by antitumor drugs.

Minotti G.

J Pharmacol Exp Ther. 2013 Sep;346(3):343-9. doi: 10.1124/jpet.113.204057. Epub 2013 Jul 1. Review.

PMID:
23818683
43.

The novel anthracenedione, pixantrone, lacks redox activity and inhibits doxorubicinol formation in human myocardium: insight to explain the cardiac safety of pixantrone in doxorubicin-treated patients.

Salvatorelli E, Menna P, Paz OG, Chello M, Covino E, Singer JW, Minotti G.

J Pharmacol Exp Ther. 2013 Feb;344(2):467-78. doi: 10.1124/jpet.112.200568. Epub 2012 Nov 28.

PMID:
23192654
44.

Pharmacokinetics of pegylated liposomal doxorubicin administered by intraoperative hyperthermic intraperitoneal chemotherapy to patients with advanced ovarian cancer and peritoneal carcinomatosis.

Salvatorelli E, De Tursi M, Menna P, Carella C, Massari R, Colasante A, Iacobelli S, Minotti G.

Drug Metab Dispos. 2012 Dec;40(12):2365-73. doi: 10.1124/dmd.112.047480. Epub 2012 Sep 12.

PMID:
22972909
45.

Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model. II. Amrubicin shows metabolic advantages over doxorubicin and epirubicin.

Salvatorelli E, Menna P, Gonzalez Paz O, Surapaneni S, Aukerman SL, Chello M, Covino E, Sung V, Minotti G.

J Pharmacol Exp Ther. 2012 May;341(2):474-83. doi: 10.1124/jpet.111.190264. Epub 2012 Feb 15.

PMID:
22338034
46.

Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model. I. Amrubicin accumulates to a lower level than doxorubicin or epirubicin.

Salvatorelli E, Menna P, Surapaneni S, Aukerman SL, Chello M, Covino E, Sung V, Minotti G.

J Pharmacol Exp Ther. 2012 May;341(2):464-73. doi: 10.1124/jpet.111.190256. Epub 2012 Feb 15.

PMID:
22338033
47.

Clinical activity and cardiac tolerability of non-pegylated liposomal doxorubicin in breast cancer: a synthetic review.

Airoldi M, Amadori D, Barni S, Cinieri S, De Placido S, Di Leo A, Gennari A, Iacobelli S, Ionta MT, Lorusso V, Lotrionte M, Marchetti P, Mattioli R, Minotti G, Pronzato P, Rosti G, Tondini CA, Veronesi A.

Tumori. 2011 Nov-Dec;97(6):690-2. doi: 10.1700/1018.11082. Review.

PMID:
22322832
48.

Managing cardiac risk factors in oncology clinical trials.

Tsimberidou AM, Minotti G, Cardinale D.

Tex Heart Inst J. 2011;38(3):266-7. Review. No abstract available.

49.

Anthracycline cardiotoxicity.

Menna P, Paz OG, Chello M, Covino E, Salvatorelli E, Minotti G.

Expert Opin Drug Saf. 2012 May;11 Suppl 1:S21-36. doi: 10.1517/14740338.2011.589834. Epub 2011 Jun 2. Review.

PMID:
21635149
50.

Matters of the heart: the case of TNFalpha-targeting drugs.

Cacciapaglia F, Menna P, Navarini L, Afeltra A, Salvatorelli E, Minotti G.

Mol Interv. 2011 Apr;11(2):79-87. doi: 10.1124/mi.11.2.4. No abstract available.

PMID:
21540466

Supplemental Content

Loading ...
Support Center